Media coverage about Covidien (NYSE:COV) has been trending somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Covidien earned a media sentiment score of 0.05 on Accern’s scale. Accern also gave news coverage about the healthcare company an impact score of 47.5641129844019 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Here are some of the media stories that may have impacted Accern’s rankings:

COPYRIGHT VIOLATION NOTICE: This news story was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/08/03/covidien-cov-receiving-somewhat-positive-press-coverage-analysis-finds.html.

About Covidien

Covidien Public Limited Company is a healthcare products company. The Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings. The Company’s brands include Kendall, Nellcor, Puritan Bennett and Valleylab, among others. It has a presence in more than 70 countries, with products sold in over 150 countries.

Receive News & Stock Ratings for Covidien Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Covidien Ltd and related stocks with our FREE daily email newsletter.